Type 1 Diabetes Drugs

Type 1 Diabetes Drugs Comprehensive Study by Type (Insulins, Symlin), Intake Duration (Split or mixed, Split or mixed variant, Multiple daily injections (MDI), Continuous subcutaneous insulin infusion (CSII)), Insulin Group (Rapid-acting, Regular or short-acting, Intermediate-acting, Long-acting), Symptoms (Polyuria, Polydipsia, Polyphagia, Unexplained weight loss) Players and Region - Global Market Outlook to 2026

Type 1 Diabetes Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Type 1 Diabetes Drugs Market?

The Type 1 diabetes drugs are practised to treat the type 1 diabetic condition and are additionally known as Type 1 diabetes mellitus. Type 1 diabetes is a disease wherein the pancreas produce very little or no insulin at all. Insulin is a hormone that allows sugar (glucose) to enter cells to produce energy. People suffering from type 1 diabetes have to take daily insulin injection to keep body glucose in the normal range. Without insulin injection, the patient may die. In type 1 diabetes condition, the body’s immune system attacks & destroy most of the beta cells in the pancreas. Different factors, including genetics and some viruses, may contribute to type 1 diabetes. Although type 1 diabetes usually appears during childhood or adolescence, however, it can also develop in adults.

The market study is being classified by Type (Insulins and Symlin) and major geographies with country level break-up.

Boehringer Ingelheim (Germany), Diamyd Therapeutics AB (Sweden), Novo Nordisk (Denmark), Sanofi (France), Eli Lily (United States), Adocia (France), Astellas Pharma (Japan), AstraZeneca (United Kingdom) and BHV Pharma (United States) are some of the key players profiled in the study.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Type 1 Diabetes Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Type 1 Diabetes Drugs market by Type, Application and Region.

On the basis of geography, the market of Type 1 Diabetes Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing occurrence of type 1 diabetes
  • The rising awareness about the type 1 diabetes and availability of its treatment drugs

Market Trend
  • High demand for the artificial pancreas and home infusion therapy for diabetes treatment trending

Restraints
  • The high cost of insulin delivery systems

Opportunities
  • The rising number of chronic diseases associated with diabetes

Challenges
  • Side effects associated with diabetes therapies could lead to a challenge


Market Leaders and some development strategies
In September 2019, vertex pharmaceuticals an American biopharmaceutical company acquire semma therapeutics with a goal of developing curative cell-based treatments for type 1 diabetes. Semma has demonstrated a differentiated approach to treat type 1 diabetes, a serious disease affecting over one million people in the United States alone.
In December 2020, A new initiative launched by the diabetes charity JDRF aims to broaden screening for type 1 diabetes risk for the general population of the United States, the Screen Costing USD 55 Is Launched. The test costs USD 55, but for those with financial hardship, JDRF will charge just USD 10. The organization is planning a public awareness campaign as well as a clinician education program via MedIQ.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Type 1 Diabetes Drugs Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Report Objectives / Segmentation Covered

By Type
  • Insulins
  • Symlin
By Intake Duration
  • Split or mixed
  • Split or mixed variant
  • Multiple daily injections (MDI)
  • Continuous subcutaneous insulin infusion (CSII)

By Insulin Group
  • Rapid-acting
  • Regular or short-acting
  • Intermediate-acting
  • Long-acting

By Symptoms
  • Polyuria
  • Polydipsia
  • Polyphagia
  • Unexplained weight loss

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing occurrence of type 1 diabetes
      • 3.2.2. The rising awareness about the type 1 diabetes and availability of its treatment drugs
    • 3.3. Market Challenges
      • 3.3.1. Side effects associated with diabetes therapies could lead to a challenge
    • 3.4. Market Trends
      • 3.4.1. High demand for the artificial pancreas and home infusion therapy for diabetes treatment trending
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Type 1 Diabetes Drugs, by Type, Intake Duration, Insulin Group, Symptoms and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Type 1 Diabetes Drugs (Value)
      • 5.2.1. Global Type 1 Diabetes Drugs by: Type (Value)
        • 5.2.1.1. Insulins
        • 5.2.1.2. Symlin
      • 5.2.2. Global Type 1 Diabetes Drugs by: Intake Duration (Value)
        • 5.2.2.1. Split or mixed
        • 5.2.2.2. Split or mixed variant
        • 5.2.2.3. Multiple daily injections (MDI)
        • 5.2.2.4. Continuous subcutaneous insulin infusion (CSII)
      • 5.2.3. Global Type 1 Diabetes Drugs by: Insulin Group (Value)
        • 5.2.3.1. Rapid-acting
        • 5.2.3.2. Regular or short-acting
        • 5.2.3.3. Intermediate-acting
        • 5.2.3.4. Long-acting
      • 5.2.4. Global Type 1 Diabetes Drugs by: Symptoms (Value)
        • 5.2.4.1. Polyuria
        • 5.2.4.2. Polydipsia
        • 5.2.4.3. Polyphagia
        • 5.2.4.4. Unexplained weight loss
      • 5.2.5. Global Type 1 Diabetes Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Type 1 Diabetes Drugs (Volume)
      • 5.3.1. Global Type 1 Diabetes Drugs by: Type (Volume)
        • 5.3.1.1. Insulins
        • 5.3.1.2. Symlin
      • 5.3.2. Global Type 1 Diabetes Drugs by: Intake Duration (Volume)
        • 5.3.2.1. Split or mixed
        • 5.3.2.2. Split or mixed variant
        • 5.3.2.3. Multiple daily injections (MDI)
        • 5.3.2.4. Continuous subcutaneous insulin infusion (CSII)
      • 5.3.3. Global Type 1 Diabetes Drugs by: Insulin Group (Volume)
        • 5.3.3.1. Rapid-acting
        • 5.3.3.2. Regular or short-acting
        • 5.3.3.3. Intermediate-acting
        • 5.3.3.4. Long-acting
      • 5.3.4. Global Type 1 Diabetes Drugs by: Symptoms (Volume)
        • 5.3.4.1. Polyuria
        • 5.3.4.2. Polydipsia
        • 5.3.4.3. Polyphagia
        • 5.3.4.4. Unexplained weight loss
      • 5.3.5. Global Type 1 Diabetes Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Type 1 Diabetes Drugs (Price)
      • 5.4.1. Global Type 1 Diabetes Drugs by: Type (Price)
  • 6. Type 1 Diabetes Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boehringer Ingelheim (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Diamyd Therapeutics AB (Sweden)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novo Nordisk (Denmark)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lily (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Adocia (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Astellas Pharma (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BHV Pharma (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Type 1 Diabetes Drugs Sale, by Type, Intake Duration, Insulin Group, Symptoms and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Type 1 Diabetes Drugs (Value)
      • 7.2.1. Global Type 1 Diabetes Drugs by: Type (Value)
        • 7.2.1.1. Insulins
        • 7.2.1.2. Symlin
      • 7.2.2. Global Type 1 Diabetes Drugs by: Intake Duration (Value)
        • 7.2.2.1. Split or mixed
        • 7.2.2.2. Split or mixed variant
        • 7.2.2.3. Multiple daily injections (MDI)
        • 7.2.2.4. Continuous subcutaneous insulin infusion (CSII)
      • 7.2.3. Global Type 1 Diabetes Drugs by: Insulin Group (Value)
        • 7.2.3.1. Rapid-acting
        • 7.2.3.2. Regular or short-acting
        • 7.2.3.3. Intermediate-acting
        • 7.2.3.4. Long-acting
      • 7.2.4. Global Type 1 Diabetes Drugs by: Symptoms (Value)
        • 7.2.4.1. Polyuria
        • 7.2.4.2. Polydipsia
        • 7.2.4.3. Polyphagia
        • 7.2.4.4. Unexplained weight loss
      • 7.2.5. Global Type 1 Diabetes Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Type 1 Diabetes Drugs (Volume)
      • 7.3.1. Global Type 1 Diabetes Drugs by: Type (Volume)
        • 7.3.1.1. Insulins
        • 7.3.1.2. Symlin
      • 7.3.2. Global Type 1 Diabetes Drugs by: Intake Duration (Volume)
        • 7.3.2.1. Split or mixed
        • 7.3.2.2. Split or mixed variant
        • 7.3.2.3. Multiple daily injections (MDI)
        • 7.3.2.4. Continuous subcutaneous insulin infusion (CSII)
      • 7.3.3. Global Type 1 Diabetes Drugs by: Insulin Group (Volume)
        • 7.3.3.1. Rapid-acting
        • 7.3.3.2. Regular or short-acting
        • 7.3.3.3. Intermediate-acting
        • 7.3.3.4. Long-acting
      • 7.3.4. Global Type 1 Diabetes Drugs by: Symptoms (Volume)
        • 7.3.4.1. Polyuria
        • 7.3.4.2. Polydipsia
        • 7.3.4.3. Polyphagia
        • 7.3.4.4. Unexplained weight loss
      • 7.3.5. Global Type 1 Diabetes Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Type 1 Diabetes Drugs (Price)
      • 7.4.1. Global Type 1 Diabetes Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Type 1 Diabetes Drugs: by Type(USD Million)
  • Table 2. Type 1 Diabetes Drugs Insulins , by Region USD Million (2015-2020)
  • Table 3. Type 1 Diabetes Drugs Symlin , by Region USD Million (2015-2020)
  • Table 4. Type 1 Diabetes Drugs: by Intake Duration(USD Million)
  • Table 5. Type 1 Diabetes Drugs Split or mixed , by Region USD Million (2015-2020)
  • Table 6. Type 1 Diabetes Drugs Split or mixed variant , by Region USD Million (2015-2020)
  • Table 7. Type 1 Diabetes Drugs Multiple daily injections (MDI) , by Region USD Million (2015-2020)
  • Table 8. Type 1 Diabetes Drugs Continuous subcutaneous insulin infusion (CSII) , by Region USD Million (2015-2020)
  • Table 9. Type 1 Diabetes Drugs: by Insulin Group(USD Million)
  • Table 10. Type 1 Diabetes Drugs Rapid-acting , by Region USD Million (2015-2020)
  • Table 11. Type 1 Diabetes Drugs Regular or short-acting , by Region USD Million (2015-2020)
  • Table 12. Type 1 Diabetes Drugs Intermediate-acting , by Region USD Million (2015-2020)
  • Table 13. Type 1 Diabetes Drugs Long-acting , by Region USD Million (2015-2020)
  • Table 14. Type 1 Diabetes Drugs: by Symptoms(USD Million)
  • Table 15. Type 1 Diabetes Drugs Polyuria , by Region USD Million (2015-2020)
  • Table 16. Type 1 Diabetes Drugs Polydipsia , by Region USD Million (2015-2020)
  • Table 17. Type 1 Diabetes Drugs Polyphagia , by Region USD Million (2015-2020)
  • Table 18. Type 1 Diabetes Drugs Unexplained weight loss , by Region USD Million (2015-2020)
  • Table 19. South America Type 1 Diabetes Drugs, by Country USD Million (2015-2020)
  • Table 20. South America Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 21. South America Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 22. South America Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 23. South America Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 24. Brazil Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 25. Brazil Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 26. Brazil Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 27. Brazil Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 28. Argentina Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 29. Argentina Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 30. Argentina Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 31. Argentina Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 32. Rest of South America Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 33. Rest of South America Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 34. Rest of South America Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 35. Rest of South America Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 36. Asia Pacific Type 1 Diabetes Drugs, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 38. Asia Pacific Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 39. Asia Pacific Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 40. Asia Pacific Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 41. China Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 42. China Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 43. China Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 44. China Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 45. Japan Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 46. Japan Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 47. Japan Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 48. Japan Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 49. India Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 50. India Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 51. India Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 52. India Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 53. South Korea Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 54. South Korea Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 55. South Korea Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 56. South Korea Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 57. Taiwan Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 58. Taiwan Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 59. Taiwan Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 60. Taiwan Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 61. Australia Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 62. Australia Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 63. Australia Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 64. Australia Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 69. Europe Type 1 Diabetes Drugs, by Country USD Million (2015-2020)
  • Table 70. Europe Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 71. Europe Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 72. Europe Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 73. Europe Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 74. Germany Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 75. Germany Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 76. Germany Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 77. Germany Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 78. France Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 79. France Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 80. France Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 81. France Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 82. Italy Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 83. Italy Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 84. Italy Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 85. Italy Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 86. United Kingdom Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 87. United Kingdom Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 88. United Kingdom Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 89. United Kingdom Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 90. Netherlands Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 91. Netherlands Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 92. Netherlands Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 93. Netherlands Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 94. Rest of Europe Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 95. Rest of Europe Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 96. Rest of Europe Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 97. Rest of Europe Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 98. MEA Type 1 Diabetes Drugs, by Country USD Million (2015-2020)
  • Table 99. MEA Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 100. MEA Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 101. MEA Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 102. MEA Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 103. Middle East Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 104. Middle East Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 105. Middle East Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 106. Middle East Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 107. Africa Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 108. Africa Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 109. Africa Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 110. Africa Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 111. North America Type 1 Diabetes Drugs, by Country USD Million (2015-2020)
  • Table 112. North America Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 113. North America Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 114. North America Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 115. North America Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 116. United States Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 117. United States Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 118. United States Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 119. United States Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 120. Canada Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 121. Canada Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 122. Canada Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 123. Canada Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 124. Mexico Type 1 Diabetes Drugs, by Type USD Million (2015-2020)
  • Table 125. Mexico Type 1 Diabetes Drugs, by Intake Duration USD Million (2015-2020)
  • Table 126. Mexico Type 1 Diabetes Drugs, by Insulin Group USD Million (2015-2020)
  • Table 127. Mexico Type 1 Diabetes Drugs, by Symptoms USD Million (2015-2020)
  • Table 128. Type 1 Diabetes Drugs Sales: by Type()
  • Table 129. Type 1 Diabetes Drugs Sales Insulins , by Region (2015-2020)
  • Table 130. Type 1 Diabetes Drugs Sales Symlin , by Region (2015-2020)
  • Table 131. Type 1 Diabetes Drugs Sales: by Intake Duration()
  • Table 132. Type 1 Diabetes Drugs Sales Split or mixed , by Region (2015-2020)
  • Table 133. Type 1 Diabetes Drugs Sales Split or mixed variant , by Region (2015-2020)
  • Table 134. Type 1 Diabetes Drugs Sales Multiple daily injections (MDI) , by Region (2015-2020)
  • Table 135. Type 1 Diabetes Drugs Sales Continuous subcutaneous insulin infusion (CSII) , by Region (2015-2020)
  • Table 136. Type 1 Diabetes Drugs Sales: by Insulin Group()
  • Table 137. Type 1 Diabetes Drugs Sales Rapid-acting , by Region (2015-2020)
  • Table 138. Type 1 Diabetes Drugs Sales Regular or short-acting , by Region (2015-2020)
  • Table 139. Type 1 Diabetes Drugs Sales Intermediate-acting , by Region (2015-2020)
  • Table 140. Type 1 Diabetes Drugs Sales Long-acting , by Region (2015-2020)
  • Table 141. Type 1 Diabetes Drugs Sales: by Symptoms()
  • Table 142. Type 1 Diabetes Drugs Sales Polyuria , by Region (2015-2020)
  • Table 143. Type 1 Diabetes Drugs Sales Polydipsia , by Region (2015-2020)
  • Table 144. Type 1 Diabetes Drugs Sales Polyphagia , by Region (2015-2020)
  • Table 145. Type 1 Diabetes Drugs Sales Unexplained weight loss , by Region (2015-2020)
  • Table 146. South America Type 1 Diabetes Drugs Sales, by Country (2015-2020)
  • Table 147. South America Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 148. South America Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 149. South America Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 150. South America Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 151. Brazil Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 152. Brazil Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 153. Brazil Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 154. Brazil Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 155. Argentina Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 156. Argentina Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 157. Argentina Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 158. Argentina Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 159. Rest of South America Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 160. Rest of South America Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 161. Rest of South America Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 162. Rest of South America Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 163. Asia Pacific Type 1 Diabetes Drugs Sales, by Country (2015-2020)
  • Table 164. Asia Pacific Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 165. Asia Pacific Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 166. Asia Pacific Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 167. Asia Pacific Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 168. China Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 169. China Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 170. China Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 171. China Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 172. Japan Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 173. Japan Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 174. Japan Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 175. Japan Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 176. India Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 177. India Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 178. India Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 179. India Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 180. South Korea Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 181. South Korea Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 182. South Korea Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 183. South Korea Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 184. Taiwan Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 185. Taiwan Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 186. Taiwan Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 187. Taiwan Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 188. Australia Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 189. Australia Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 190. Australia Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 191. Australia Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 192. Rest of Asia-Pacific Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 193. Rest of Asia-Pacific Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 194. Rest of Asia-Pacific Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 195. Rest of Asia-Pacific Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 196. Europe Type 1 Diabetes Drugs Sales, by Country (2015-2020)
  • Table 197. Europe Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 198. Europe Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 199. Europe Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 200. Europe Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 201. Germany Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 202. Germany Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 203. Germany Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 204. Germany Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 205. France Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 206. France Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 207. France Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 208. France Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 209. Italy Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 210. Italy Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 211. Italy Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 212. Italy Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 213. United Kingdom Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 214. United Kingdom Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 215. United Kingdom Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 216. United Kingdom Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 217. Netherlands Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 218. Netherlands Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 219. Netherlands Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 220. Netherlands Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 221. Rest of Europe Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 222. Rest of Europe Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 223. Rest of Europe Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 224. Rest of Europe Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 225. MEA Type 1 Diabetes Drugs Sales, by Country (2015-2020)
  • Table 226. MEA Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 227. MEA Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 228. MEA Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 229. MEA Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 230. Middle East Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 231. Middle East Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 232. Middle East Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 233. Middle East Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 234. Africa Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 235. Africa Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 236. Africa Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 237. Africa Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 238. North America Type 1 Diabetes Drugs Sales, by Country (2015-2020)
  • Table 239. North America Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 240. North America Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 241. North America Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 242. North America Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 243. United States Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 244. United States Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 245. United States Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 246. United States Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 247. Canada Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 248. Canada Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 249. Canada Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 250. Canada Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 251. Mexico Type 1 Diabetes Drugs Sales, by Type (2015-2020)
  • Table 252. Mexico Type 1 Diabetes Drugs Sales, by Intake Duration (2015-2020)
  • Table 253. Mexico Type 1 Diabetes Drugs Sales, by Insulin Group (2015-2020)
  • Table 254. Mexico Type 1 Diabetes Drugs Sales, by Symptoms (2015-2020)
  • Table 255. Type 1 Diabetes Drugs: by Type(USD/Units)
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Type 1 Diabetes Drugs: by Type(USD Million)
  • Table 266. Type 1 Diabetes Drugs Insulins , by Region USD Million (2021-2026)
  • Table 267. Type 1 Diabetes Drugs Symlin , by Region USD Million (2021-2026)
  • Table 268. Type 1 Diabetes Drugs: by Intake Duration(USD Million)
  • Table 269. Type 1 Diabetes Drugs Split or mixed , by Region USD Million (2021-2026)
  • Table 270. Type 1 Diabetes Drugs Split or mixed variant , by Region USD Million (2021-2026)
  • Table 271. Type 1 Diabetes Drugs Multiple daily injections (MDI) , by Region USD Million (2021-2026)
  • Table 272. Type 1 Diabetes Drugs Continuous subcutaneous insulin infusion (CSII) , by Region USD Million (2021-2026)
  • Table 273. Type 1 Diabetes Drugs: by Insulin Group(USD Million)
  • Table 274. Type 1 Diabetes Drugs Rapid-acting , by Region USD Million (2021-2026)
  • Table 275. Type 1 Diabetes Drugs Regular or short-acting , by Region USD Million (2021-2026)
  • Table 276. Type 1 Diabetes Drugs Intermediate-acting , by Region USD Million (2021-2026)
  • Table 277. Type 1 Diabetes Drugs Long-acting , by Region USD Million (2021-2026)
  • Table 278. Type 1 Diabetes Drugs: by Symptoms(USD Million)
  • Table 279. Type 1 Diabetes Drugs Polyuria , by Region USD Million (2021-2026)
  • Table 280. Type 1 Diabetes Drugs Polydipsia , by Region USD Million (2021-2026)
  • Table 281. Type 1 Diabetes Drugs Polyphagia , by Region USD Million (2021-2026)
  • Table 282. Type 1 Diabetes Drugs Unexplained weight loss , by Region USD Million (2021-2026)
  • Table 283. South America Type 1 Diabetes Drugs, by Country USD Million (2021-2026)
  • Table 284. South America Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 285. South America Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 286. South America Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 287. South America Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 288. Brazil Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 289. Brazil Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 290. Brazil Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 291. Brazil Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 292. Argentina Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 293. Argentina Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 294. Argentina Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 295. Argentina Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 296. Rest of South America Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 297. Rest of South America Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 298. Rest of South America Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 299. Rest of South America Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 300. Asia Pacific Type 1 Diabetes Drugs, by Country USD Million (2021-2026)
  • Table 301. Asia Pacific Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 302. Asia Pacific Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 303. Asia Pacific Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 304. Asia Pacific Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 305. China Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 306. China Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 307. China Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 308. China Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 309. Japan Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 310. Japan Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 311. Japan Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 312. Japan Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 313. India Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 314. India Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 315. India Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 316. India Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 317. South Korea Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 318. South Korea Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 319. South Korea Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 320. South Korea Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 321. Taiwan Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 322. Taiwan Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 323. Taiwan Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 324. Taiwan Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 325. Australia Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 326. Australia Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 327. Australia Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 328. Australia Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 329. Rest of Asia-Pacific Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 330. Rest of Asia-Pacific Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 331. Rest of Asia-Pacific Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 332. Rest of Asia-Pacific Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 333. Europe Type 1 Diabetes Drugs, by Country USD Million (2021-2026)
  • Table 334. Europe Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 335. Europe Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 336. Europe Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 337. Europe Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 338. Germany Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 339. Germany Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 340. Germany Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 341. Germany Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 342. France Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 343. France Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 344. France Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 345. France Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 346. Italy Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 347. Italy Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 348. Italy Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 349. Italy Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 350. United Kingdom Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 351. United Kingdom Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 352. United Kingdom Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 353. United Kingdom Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 354. Netherlands Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 355. Netherlands Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 356. Netherlands Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 357. Netherlands Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 358. Rest of Europe Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 359. Rest of Europe Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 360. Rest of Europe Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 361. Rest of Europe Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 362. MEA Type 1 Diabetes Drugs, by Country USD Million (2021-2026)
  • Table 363. MEA Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 364. MEA Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 365. MEA Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 366. MEA Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 367. Middle East Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 368. Middle East Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 369. Middle East Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 370. Middle East Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 371. Africa Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 372. Africa Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 373. Africa Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 374. Africa Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 375. North America Type 1 Diabetes Drugs, by Country USD Million (2021-2026)
  • Table 376. North America Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 377. North America Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 378. North America Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 379. North America Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 380. United States Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 381. United States Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 382. United States Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 383. United States Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 384. Canada Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 385. Canada Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 386. Canada Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 387. Canada Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 388. Mexico Type 1 Diabetes Drugs, by Type USD Million (2021-2026)
  • Table 389. Mexico Type 1 Diabetes Drugs, by Intake Duration USD Million (2021-2026)
  • Table 390. Mexico Type 1 Diabetes Drugs, by Insulin Group USD Million (2021-2026)
  • Table 391. Mexico Type 1 Diabetes Drugs, by Symptoms USD Million (2021-2026)
  • Table 392. Type 1 Diabetes Drugs Sales: by Type()
  • Table 393. Type 1 Diabetes Drugs Sales Insulins , by Region (2021-2026)
  • Table 394. Type 1 Diabetes Drugs Sales Symlin , by Region (2021-2026)
  • Table 395. Type 1 Diabetes Drugs Sales: by Intake Duration()
  • Table 396. Type 1 Diabetes Drugs Sales Split or mixed , by Region (2021-2026)
  • Table 397. Type 1 Diabetes Drugs Sales Split or mixed variant , by Region (2021-2026)
  • Table 398. Type 1 Diabetes Drugs Sales Multiple daily injections (MDI) , by Region (2021-2026)
  • Table 399. Type 1 Diabetes Drugs Sales Continuous subcutaneous insulin infusion (CSII) , by Region (2021-2026)
  • Table 400. Type 1 Diabetes Drugs Sales: by Insulin Group()
  • Table 401. Type 1 Diabetes Drugs Sales Rapid-acting , by Region (2021-2026)
  • Table 402. Type 1 Diabetes Drugs Sales Regular or short-acting , by Region (2021-2026)
  • Table 403. Type 1 Diabetes Drugs Sales Intermediate-acting , by Region (2021-2026)
  • Table 404. Type 1 Diabetes Drugs Sales Long-acting , by Region (2021-2026)
  • Table 405. Type 1 Diabetes Drugs Sales: by Symptoms()
  • Table 406. Type 1 Diabetes Drugs Sales Polyuria , by Region (2021-2026)
  • Table 407. Type 1 Diabetes Drugs Sales Polydipsia , by Region (2021-2026)
  • Table 408. Type 1 Diabetes Drugs Sales Polyphagia , by Region (2021-2026)
  • Table 409. Type 1 Diabetes Drugs Sales Unexplained weight loss , by Region (2021-2026)
  • Table 410. South America Type 1 Diabetes Drugs Sales, by Country (2021-2026)
  • Table 411. South America Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 412. South America Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 413. South America Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 414. South America Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 415. Brazil Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 416. Brazil Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 417. Brazil Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 418. Brazil Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 419. Argentina Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 420. Argentina Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 421. Argentina Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 422. Argentina Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 423. Rest of South America Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 424. Rest of South America Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 425. Rest of South America Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 426. Rest of South America Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 427. Asia Pacific Type 1 Diabetes Drugs Sales, by Country (2021-2026)
  • Table 428. Asia Pacific Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 429. Asia Pacific Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 430. Asia Pacific Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 431. Asia Pacific Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 432. China Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 433. China Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 434. China Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 435. China Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 436. Japan Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 437. Japan Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 438. Japan Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 439. Japan Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 440. India Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 441. India Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 442. India Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 443. India Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 444. South Korea Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 445. South Korea Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 446. South Korea Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 447. South Korea Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 448. Taiwan Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 449. Taiwan Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 450. Taiwan Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 451. Taiwan Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 452. Australia Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 453. Australia Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 454. Australia Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 455. Australia Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 456. Rest of Asia-Pacific Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 457. Rest of Asia-Pacific Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 458. Rest of Asia-Pacific Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 459. Rest of Asia-Pacific Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 460. Europe Type 1 Diabetes Drugs Sales, by Country (2021-2026)
  • Table 461. Europe Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 462. Europe Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 463. Europe Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 464. Europe Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 465. Germany Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 466. Germany Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 467. Germany Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 468. Germany Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 469. France Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 470. France Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 471. France Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 472. France Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 473. Italy Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 474. Italy Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 475. Italy Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 476. Italy Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 477. United Kingdom Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 478. United Kingdom Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 479. United Kingdom Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 480. United Kingdom Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 481. Netherlands Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 482. Netherlands Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 483. Netherlands Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 484. Netherlands Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 485. Rest of Europe Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 486. Rest of Europe Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 487. Rest of Europe Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 488. Rest of Europe Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 489. MEA Type 1 Diabetes Drugs Sales, by Country (2021-2026)
  • Table 490. MEA Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 491. MEA Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 492. MEA Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 493. MEA Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 494. Middle East Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 495. Middle East Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 496. Middle East Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 497. Middle East Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 498. Africa Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 499. Africa Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 500. Africa Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 501. Africa Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 502. North America Type 1 Diabetes Drugs Sales, by Country (2021-2026)
  • Table 503. North America Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 504. North America Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 505. North America Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 506. North America Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 507. United States Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 508. United States Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 509. United States Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 510. United States Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 511. Canada Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 512. Canada Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 513. Canada Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 514. Canada Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 515. Mexico Type 1 Diabetes Drugs Sales, by Type (2021-2026)
  • Table 516. Mexico Type 1 Diabetes Drugs Sales, by Intake Duration (2021-2026)
  • Table 517. Mexico Type 1 Diabetes Drugs Sales, by Insulin Group (2021-2026)
  • Table 518. Mexico Type 1 Diabetes Drugs Sales, by Symptoms (2021-2026)
  • Table 519. Type 1 Diabetes Drugs: by Type(USD/Units)
  • Table 520. Research Programs/Design for This Report
  • Table 521. Key Data Information from Secondary Sources
  • Table 522. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Type 1 Diabetes Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Type 1 Diabetes Drugs: by Intake Duration USD Million (2015-2020)
  • Figure 6. Global Type 1 Diabetes Drugs: by Insulin Group USD Million (2015-2020)
  • Figure 7. Global Type 1 Diabetes Drugs: by Symptoms USD Million (2015-2020)
  • Figure 8. South America Type 1 Diabetes Drugs Share (%), by Country
  • Figure 9. Asia Pacific Type 1 Diabetes Drugs Share (%), by Country
  • Figure 10. Europe Type 1 Diabetes Drugs Share (%), by Country
  • Figure 11. MEA Type 1 Diabetes Drugs Share (%), by Country
  • Figure 12. North America Type 1 Diabetes Drugs Share (%), by Country
  • Figure 13. Global Type 1 Diabetes Drugs: by Type (2015-2020)
  • Figure 14. Global Type 1 Diabetes Drugs: by Intake Duration (2015-2020)
  • Figure 15. Global Type 1 Diabetes Drugs: by Insulin Group (2015-2020)
  • Figure 16. Global Type 1 Diabetes Drugs: by Symptoms (2015-2020)
  • Figure 17. South America Type 1 Diabetes Drugs Share (%), by Country
  • Figure 18. Asia Pacific Type 1 Diabetes Drugs Share (%), by Country
  • Figure 19. Europe Type 1 Diabetes Drugs Share (%), by Country
  • Figure 20. MEA Type 1 Diabetes Drugs Share (%), by Country
  • Figure 21. North America Type 1 Diabetes Drugs Share (%), by Country
  • Figure 22. Global Type 1 Diabetes Drugs: by Type USD/Units (2015-2020)
  • Figure 23. Global Type 1 Diabetes Drugs share by Players 2020 (%)
  • Figure 24. Global Type 1 Diabetes Drugs share by Players (Top 3) 2020(%)
  • Figure 25. Global Type 1 Diabetes Drugs share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 29. Diamyd Therapeutics AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 30. Diamyd Therapeutics AB (Sweden) Revenue: by Geography 2020
  • Figure 31. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 32. Novo Nordisk (Denmark) Revenue: by Geography 2020
  • Figure 33. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi (France) Revenue: by Geography 2020
  • Figure 35. Eli Lily (United States) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lily (United States) Revenue: by Geography 2020
  • Figure 37. Adocia (France) Revenue, Net Income and Gross profit
  • Figure 38. Adocia (France) Revenue: by Geography 2020
  • Figure 39. Astellas Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 40. Astellas Pharma (Japan) Revenue: by Geography 2020
  • Figure 41. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 43. BHV Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 44. BHV Pharma (United States) Revenue: by Geography 2020
  • Figure 45. Global Type 1 Diabetes Drugs: by Type USD Million (2021-2026)
  • Figure 46. Global Type 1 Diabetes Drugs: by Intake Duration USD Million (2021-2026)
  • Figure 47. Global Type 1 Diabetes Drugs: by Insulin Group USD Million (2021-2026)
  • Figure 48. Global Type 1 Diabetes Drugs: by Symptoms USD Million (2021-2026)
  • Figure 49. South America Type 1 Diabetes Drugs Share (%), by Country
  • Figure 50. Asia Pacific Type 1 Diabetes Drugs Share (%), by Country
  • Figure 51. Europe Type 1 Diabetes Drugs Share (%), by Country
  • Figure 52. MEA Type 1 Diabetes Drugs Share (%), by Country
  • Figure 53. North America Type 1 Diabetes Drugs Share (%), by Country
  • Figure 54. Global Type 1 Diabetes Drugs: by Type (2021-2026)
  • Figure 55. Global Type 1 Diabetes Drugs: by Intake Duration (2021-2026)
  • Figure 56. Global Type 1 Diabetes Drugs: by Insulin Group (2021-2026)
  • Figure 57. Global Type 1 Diabetes Drugs: by Symptoms (2021-2026)
  • Figure 58. South America Type 1 Diabetes Drugs Share (%), by Country
  • Figure 59. Asia Pacific Type 1 Diabetes Drugs Share (%), by Country
  • Figure 60. Europe Type 1 Diabetes Drugs Share (%), by Country
  • Figure 61. MEA Type 1 Diabetes Drugs Share (%), by Country
  • Figure 62. North America Type 1 Diabetes Drugs Share (%), by Country
  • Figure 63. Global Type 1 Diabetes Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Boehringer Ingelheim (Germany)
  • Diamyd Therapeutics AB (Sweden)
  • Novo Nordisk (Denmark)
  • Sanofi (France)
  • Eli Lily (United States)
  • Adocia (France)
  • Astellas Pharma (Japan)
  • AstraZeneca (United Kingdom)
  • BHV Pharma (United States)
Select User Access Type

Key Highlights of Report


Feb 2021 242 Pages 62 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Type 1 Diabetes Drugs Quantitative research analysis
Type 1 Diabetes Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Growing occurrence of type 1 diabetes " is seen as one of major growth factors of Type 1 Diabetes Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Type 1 Diabetes Drugs Report?

Have a Query? Click Here

Other Related Reports

Arthritis Drug Comprehensive Study by Type (Synthetic DMARDs, Biological DMARDs, NSAIDs, Corticosteroids, Analgesics), Application (Retail Pharmacies, Hospital Pharmacies, Drug Stores, E-Commerce), R...
$ 3750
Oxytocic Pharmaceuticals Comprehensive Study by Route of Administration (Intramuscular, Intravenous Injection/Infusion), Indication (Abortion Induced Incomplete, Inevitable Abortion, Postpartum Hemor...
$ 3750
Acemetacin Comprehensive Study by Application (Rheumatoid Arthritis, Osteoarthritis, Lower Back Pain, Postoperative Pain Reduction, Inflammation), End User (Hospitals, Pharmacy) Players and Region - ...
$ 3500
Ivosidenib Drugs Comprehensive Study by Type (60 Tablets, 30 Tablets), Application (Hospital, Pharmacy) Players and Region - Global Market Outlook to 2026
$ 3500
Tuberculosis Vaccines Comprehensive Study by Type (Immunotherapeutic Vaccines, Booster Vaccines, Others), Application (Hospitals, Clinics, Others), Testing Type (Tuberculin Skin Test (TST), TB Blood ...
$ 3500
Sulbactam Pivoxil Comprehensive Study by Application (Pharmaceutical, Research, Biosciences, Others), Form (Tablets, Powder, Suspension), Distribution Channel (Hospitals Pharmacies, Medical Stores, O...
$ 3450